A Study of BW-20507 in Chinese Healthy Subjects and Subjects With Chronic Hepatitis B

Summary

Phase 1 Study of BW-20507 in Healthy Subjects and Patients With Chronic Hepatitis B. Ia involved a single ascending dose study where healthy participants were administered one dose of BW-20507 or placebo subcutaneously. Ib involved a multiple ascending dose study where participants with chronic hepatitis B virus infection were administered with multiple doses of BW-20507 SC

Timeline

Start

2024-06-24

Primary completion

2025-11-18

Completion

2025-12-29

Drugs

Indications